• Ensysce Biosciences initiated final stage of PF614-MPAR-102 clinical study following IRB clearance.
• Previously published clinical data were already presented, showing PF614-MPAR maintained intended opioid exposure under prescribed use.
• Those results also indicated overdose-protection behavior, limiting additional opioid release when excessive oral doses were taken.
• Part 3 will be presented in future readouts, aiming to confirm protective effect across multiple dosing scenarios.
• Program supports Ensysce strategy to differentiate PF614-MPAR as a next-generation opioid with built-in oral overdose protection, extending MPAR platform toward other CNS categories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604160800ACCESSWRNAPR_____1157669) on April 16, 2026, and is solely responsible for the information contained therein.